You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRivaroxaban
Accession NumberDB06228
TypeSmall Molecule
GroupsApproved
Description

Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.

Structure
Thumb
Synonyms
BAY 59-7939
BAY59-7939
Xarelto
External Identifiers
  • BAY 59-7939
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Xareltotablet, film coated20 mg/1oralCardinal Health2011-11-05Not applicableUs
Xareltotablet, film coated15 mg/1oralJanssen Pharmaceuticals, Inc.2011-11-04Not applicableUs
Xareltotablet, film coated10 mg/1oralCardinal Health2011-07-01Not applicableUs
Xareltotablet20 mgoralBayer Inc2012-01-17Not applicableCanada
Xareltotablet15 mgoralBayer Inc2012-01-17Not applicableCanada
Xareltotablet10 mgoralBayer Inc2008-09-16Not applicableCanada
XareltokitJanssen Pharmaceuticals, Inc.2014-09-16Not applicableUs
Xareltotablet, film coated10 mg/1oralJanssen Pharmaceuticals, Inc.2011-07-01Not applicableUs
Xareltotablet, film coated15 mg/1oralCardinal Health2011-11-04Not applicableUs
Xareltotablet, film coated20 mg/1oralJanssen Pharmaceuticals, Inc.2011-11-05Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
XareltoBayer Inc
SaltsNot Available
Categories
UNII9NDF7JZ4M3
CAS number366789-02-8
WeightAverage: 435.881
Monoisotopic: 435.065569098
Chemical FormulaC19H18ClN3O5S
InChI KeyInChIKey=KGFYHTZWPPHNLQ-AWEZNQCLSA-N
InChI
InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1
IUPAC Name
5-chloro-N-{[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide
SMILES
ClC1=CC=C(S1)C(=O)NC[[email protected]]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylmorpholines. These are aromatic compounds containing a morpholine ring and a benzene ring linked to each other through a CC or a CN bond.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassOxazinanes
Sub ClassMorpholines
Direct ParentPhenylmorpholines
Alternative Parents
Substituents
  • Phenylmorpholine
  • Thiophene carboxylic acid or derivatives
  • Thiophene carboxamide
  • 2,5-disubstituted thiophene
  • Benzenoid
  • Oxazolidinone
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Thiophene
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Lactam
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationRivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurrent DVT and/or PE. Due to a lack of safety studies, it is not recommended for use in those under 18 years old. Its use is also not recommended in those with severe renal impairment (<30mL/min).
PharmacodynamicsRivaroxaban is an anticoagulant which binds directly to factor Xa. Thereafter, it effectively blocks the amplification of the coagulation cascade, preventing the formation of thrombus. Rivaroxaban is a unqiue anticoagulant for two reasons. First of all, it is does not involve antithrombin III (ATIII) to exert its anticoagulant effects. Secondly, it is an oral agent whereas the widely used unfractionated heparin and low molecular weight heparins are for parenteral use only. Although the activated partial thromboplastin time (aPTT) and HepTest (a test developed to assay low molecular weight heparins) are prolonged in a dose-dependant manner, neither test is recommended for the assessment of the pharmacodynamic effects of rivaroxaban. Anti-Xa activity and inhibition of anti-Xa activity monitoring is also not recommended despite being influenced by rivaroxaban.
Mechanism of actionRivaroxaban competitively inhibits free and clot bound factor Xa. Factor Xa is needed to activate prothrombin (factor II) to thrombin (factor IIa). Thrombin is a serine protease that is required to activate fibrinogen to fibrin, which is the loose meshwork that completes the clotting process. Since one molecule of factor Xa can generate more than 1000 molecules of thrombin, selective inhibitors of factor Xa are profoundly useful in terminating the amplification of thrombin generation. The action of rivaroxaban is irreversible.
Related Articles
AbsorptionFollowing oral administration, rivaroxaban is rapidly absorbed and reaches peak plasma concentration in 2-4 hours. Bioavailability of the 10 mg dose is >80%. However, the 15-20 mg dose have a lower bioavailability if taken in the fasted state and consequently should be taken with food.
Volume of distribution

The steady state Vd is 50 L

Protein bindingPlasma protein binding is about 92% to 95%
Metabolism

Approximately two-thirds of the dose is metabolized. It is metabolized by CYP3A4, CYP3A5, CYP2J2 and CYP-independant mechanisms

Route of eliminationApproximately two-thirds of rivaroxaban is excreted into urine (via active tubular secretion in which approximately 36% as unchanged drug and 30% as inactive metabolism). The remaining third of the administered dose is excreted via feces in which 7% is in the form of unchanged drug and 21% as inactive metabolites.
Half lifeThe terminal half life is 5-9 hours in adults and 11-13 hours in the elderly.
Clearance

Systemic clearance is approximately 10 L/h, so rivaroxaban is considered a drug with low clearance. Renal clearance is ~3-4 L/h.

ToxicityExcessive bleeding. Overdosages should be treated using activated charcoal and supportive measures such as mechanical compression and hemodynamic support. If bleeding is not controlled, the following procoagulants can be administered: activated prothrombin complex concentrate, prothrombin complex concentrate and recombinant factor VIIa. There is also a higher chance of post procedural hemorrhage compared to enoxaparin (1.55% vs. 1.39% respectively).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9966
Blood Brain Barrier+0.9462
Caco-2 permeable+0.6822
P-glycoprotein substrateNon-substrate0.5691
P-glycoprotein inhibitor IInhibitor0.6325
P-glycoprotein inhibitor IIInhibitor0.5601
Renal organic cation transporterNon-inhibitor0.7562
CYP450 2C9 substrateNon-substrate0.7866
CYP450 2D6 substrateNon-substrate0.8761
CYP450 3A4 substrateSubstrate0.5964
CYP450 1A2 substrateNon-inhibitor0.6469
CYP450 2C9 inhibitorNon-inhibitor0.7035
CYP450 2D6 inhibitorNon-inhibitor0.7516
CYP450 2C19 inhibitorInhibitor0.6475
CYP450 3A4 inhibitorNon-inhibitor0.6667
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7463
Ames testNon AMES toxic0.6162
CarcinogenicityNon-carcinogens0.8838
BiodegradationNot ready biodegradable0.9844
Rat acute toxicity2.4353 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8938
hERG inhibition (predictor II)Inhibitor0.6205
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Kit
Tabletoral
Tabletoral10 mg
Tabletoral15 mg
Tabletoral20 mg
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral15 mg/1
Tablet, film coatedoral20 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2396561 No2008-10-142020-12-11Canada
CA2547113 No2012-01-242024-11-13Canada
US7157456 No2001-02-082021-02-08Us
US7585860 No2000-12-112020-12-11Us
US7592339 No2000-12-112020-12-11Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.01 mg/mLALOGPS
logP1.74ALOGPS
logP1.9ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)13.6ChemAxon
pKa (Strongest Basic)-1.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area88.18 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity104.74 m3·mol-1ChemAxon
Polarizability43.41 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Prabhudas BODHURI, Gamini Weeratunga, “PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF.” U.S. Patent US20100273790, issued October 28, 2010.

US20100273790
General References
  1. Piccini JP, Patel MR, Mahaffey KW, Fox KA, Califf RM: Rivaroxaban, an oral direct factor Xa inhibitor. Expert Opin Investig Drugs. 2008 Jun;17(6):925-37. doi: 10.1517/13543784.17.6.925 . [PubMed:18491993 ]
  2. Alban S: Pharmacological strategies for inhibition of thrombin activity. Curr Pharm Des. 2008;14(12):1152-75. [PubMed:18473863 ]
  3. Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E: Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal. Health Technol Assess. 2009 Oct;13 Suppl 3:43-8. doi: 10.3310/hta13suppl3/07. [PubMed:19846028 ]
  4. Imberti D, Dall'Asta C, Pierfranceschi MG: Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review. Intern Emerg Med. 2009 Dec;4(6):471-7. doi: 10.1007/s11739-009-0293-9. [PubMed:19696978 ]
  5. Alexander D, Jeremias A: Rivaroxaban in the contemporary treatment of acute coronary syndromes. Expert Opin Investig Drugs. 2011 Jun;20(6):849-57. doi: 10.1517/13543784.2011.580274. Epub 2011 May 10. [PubMed:21554163 ]
  6. Cabral KP: Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis. 2013 Aug;36(2):133-40. doi: 10.1007/s11239-013-0929-5. [PubMed:23645472 ]
External Links
ATC CodesB01AF01
AHFS Codes
  • 20.12.04.14
PDB EntriesNot Available
FDA labelDownload (537 KB)
MSDSDownload (480 KB)
Interactions
Drug Interactions
Drug
AbciximabAbciximab may increase the anticoagulant activities of Rivaroxaban.
AcenocoumarolAcenocoumarol may increase the anticoagulant activities of Rivaroxaban.
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Rivaroxaban.
AlteplaseAlteplase may increase the anticoagulant activities of Rivaroxaban.
AnagrelideAnagrelide may increase the anticoagulant activities of Rivaroxaban.
AnistreplaseAnistreplase may increase the anticoagulant activities of Rivaroxaban.
ApixabanApixaban may increase the anticoagulant activities of Rivaroxaban.
ArgatrobanArgatroban may increase the anticoagulant activities of Rivaroxaban.
BexaroteneThe serum concentration of Rivaroxaban can be decreased when it is combined with Bexarotene.
BivalirudinBivalirudin may increase the anticoagulant activities of Rivaroxaban.
BosentanThe serum concentration of Rivaroxaban can be decreased when it is combined with Bosentan.
CangrelorCangrelor may increase the anticoagulant activities of Rivaroxaban.
CarbamazepineThe serum concentration of Rivaroxaban can be decreased when it is combined with Carbamazepine.
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Rivaroxaban.
CilostazolCilostazol may increase the anticoagulant activities of Rivaroxaban.
CitalopramCitalopram may increase the anticoagulant activities of Rivaroxaban.
Citric AcidCitric Acid may increase the anticoagulant activities of Rivaroxaban.
ClarithromycinThe serum concentration of Rivaroxaban can be increased when it is combined with Clarithromycin.
ClopidogrelClopidogrel may increase the anticoagulant activities of Rivaroxaban.
CobicistatThe serum concentration of Rivaroxaban can be increased when it is combined with Cobicistat.
CollagenaseThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Collagenase.
CrizotinibThe serum concentration of Rivaroxaban can be increased when it is combined with Crizotinib.
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Rivaroxaban.
DabrafenibThe serum concentration of Rivaroxaban can be decreased when it is combined with Dabrafenib.
DalteparinDalteparin may increase the anticoagulant activities of Rivaroxaban.
DanaparoidDanaparoid may increase the anticoagulant activities of Rivaroxaban.
DarunavirThe serum concentration of Rivaroxaban can be increased when it is combined with Darunavir.
DasatinibDasatinib may increase the anticoagulant activities of Rivaroxaban.
DeferasiroxThe serum concentration of Rivaroxaban can be decreased when it is combined with Deferasirox.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Deoxycholic Acid.
DesirudinDesirudin may increase the anticoagulant activities of Rivaroxaban.
DesogestrelThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Desogestrel.
DesvenlafaxineDesvenlafaxine may increase the anticoagulant activities of Rivaroxaban.
DiclofenacDiclofenac may increase the anticoagulant activities of Rivaroxaban.
DicoumarolDicoumarol may increase the anticoagulant activities of Rivaroxaban.
DiflunisalDiflunisal may increase the anticoagulant activities of Rivaroxaban.
DipyridamoleDipyridamole may increase the anticoagulant activities of Rivaroxaban.
DronedaroneThe serum concentration of Rivaroxaban can be increased when it is combined with Dronedarone.
DuloxetineDuloxetine may increase the anticoagulant activities of Rivaroxaban.
DydrogesteroneThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Dydrogesterone.
Edetic AcidEdetic Acid may increase the anticoagulant activities of Rivaroxaban.
EdoxabanEdoxaban may increase the anticoagulant activities of Rivaroxaban.
EnoxaparinEnoxaparin may increase the anticoagulant activities of Rivaroxaban.
EnzalutamideThe serum concentration of Rivaroxaban can be decreased when it is combined with Enzalutamide.
EptifibatideEptifibatide may increase the anticoagulant activities of Rivaroxaban.
ErythromycinThe serum concentration of Rivaroxaban can be increased when it is combined with Erythromycin.
EscitalopramEscitalopram may increase the anticoagulant activities of Rivaroxaban.
Ethyl biscoumacetateEthyl biscoumacetate may increase the anticoagulant activities of Rivaroxaban.
EtodolacEtodolac may increase the anticoagulant activities of Rivaroxaban.
FenoprofenFenoprofen may increase the anticoagulant activities of Rivaroxaban.
FloctafenineFloctafenine may increase the anticoagulant activities of Rivaroxaban.
FluoxetineFluoxetine may increase the anticoagulant activities of Rivaroxaban.
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Rivaroxaban.
FluvoxamineFluvoxamine may increase the anticoagulant activities of Rivaroxaban.
Fondaparinux sodiumFondaparinux sodium may increase the anticoagulant activities of Rivaroxaban.
FosphenytoinThe serum concentration of Rivaroxaban can be decreased when it is combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Rivaroxaban can be increased when it is combined with Fusidic Acid.
GestodeneThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Gestodene.
HeparinHeparin may increase the anticoagulant activities of Rivaroxaban.
HomoharringtonineThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Homoharringtonine.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Ibritumomab.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Rivaroxaban.
IbuprofenIbuprofen may increase the anticoagulant activities of Rivaroxaban.
IndomethacinIndomethacin may increase the anticoagulant activities of Rivaroxaban.
InfliximabInfliximab may increase the anticoagulant activities of Rivaroxaban.
ItraconazoleThe serum concentration of Rivaroxaban can be increased when it is combined with Itraconazole.
KetoconazoleThe serum concentration of Rivaroxaban can be increased when it is combined with Ketoconazole.
KetoprofenKetoprofen may increase the anticoagulant activities of Rivaroxaban.
KetorolacKetorolac may increase the anticoagulant activities of Rivaroxaban.
LevomilnacipranLevomilnacipran may increase the anticoagulant activities of Rivaroxaban.
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Rivaroxaban.
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Rivaroxaban.
MeloxicamMeloxicam may increase the anticoagulant activities of Rivaroxaban.
MilnacipranMilnacipran may increase the anticoagulant activities of Rivaroxaban.
MitotaneThe serum concentration of Rivaroxaban can be decreased when it is combined with Mitotane.
NabumetoneNabumetone may increase the anticoagulant activities of Rivaroxaban.
NadroparinNadroparin may increase the anticoagulant activities of Rivaroxaban.
NaproxenNaproxen may increase the anticoagulant activities of Rivaroxaban.
NilotinibThe serum concentration of Rivaroxaban can be increased when it is combined with Nilotinib.
NintedanibThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Nintedanib.
ObinutuzumabThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Obinutuzumab.
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Rivaroxaban.
OxaprozinOxaprozin may increase the anticoagulant activities of Rivaroxaban.
ParoxetineParoxetine may increase the anticoagulant activities of Rivaroxaban.
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Rivaroxaban.
PhenindionePhenindione may increase the anticoagulant activities of Rivaroxaban.
PhenobarbitalThe serum concentration of Rivaroxaban can be decreased when it is combined with Phenobarbital.
PhenprocoumonPhenprocoumon may increase the anticoagulant activities of Rivaroxaban.
PhenytoinThe serum concentration of Rivaroxaban can be decreased when it is combined with Phenytoin.
PiroxicamPiroxicam may increase the anticoagulant activities of Rivaroxaban.
PrasugrelPrasugrel may increase the anticoagulant activities of Rivaroxaban.
PrimidoneThe serum concentration of Rivaroxaban can be decreased when it is combined with Primidone.
ProgesteroneThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Progesterone.
ReteplaseReteplase may increase the anticoagulant activities of Rivaroxaban.
RidogrelRidogrel may increase the anticoagulant activities of Rivaroxaban.
RifabutinThe serum concentration of Rivaroxaban can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Rivaroxaban can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Rivaroxaban can be decreased when it is combined with Rifapentine.
RitonavirThe serum concentration of Rivaroxaban can be increased when it is combined with Ritonavir.
SaquinavirThe serum concentration of Rivaroxaban can be increased when it is combined with Saquinavir.
SertralineSertraline may increase the anticoagulant activities of Rivaroxaban.
SiltuximabThe serum concentration of Rivaroxaban can be decreased when it is combined with Siltuximab.
St. John's WortThe serum concentration of Rivaroxaban can be decreased when it is combined with St. John&#39;s Wort.
StreptokinaseStreptokinase may increase the anticoagulant activities of Rivaroxaban.
SugammadexSugammadex may increase the anticoagulant activities of Rivaroxaban.
SulindacSulindac may increase the anticoagulant activities of Rivaroxaban.
SulodexideSulodexide may increase the anticoagulant activities of Rivaroxaban.
TelaprevirThe serum concentration of Rivaroxaban can be increased when it is combined with Telaprevir.
TenecteplaseTenecteplase may increase the anticoagulant activities of Rivaroxaban.
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Rivaroxaban.
TiboloneTibolone may increase the anticoagulant activities of Rivaroxaban.
TicagrelorTicagrelor may increase the anticoagulant activities of Rivaroxaban.
TiclopidineTiclopidine may increase the anticoagulant activities of Rivaroxaban.
TinzaparinTinzaparin may increase the anticoagulant activities of Rivaroxaban.
TipranavirTipranavir may increase the anticoagulant activities of Rivaroxaban.
TirofibanTirofiban may increase the anticoagulant activities of Rivaroxaban.
TocilizumabThe serum concentration of Rivaroxaban can be decreased when it is combined with Tocilizumab.
TolmetinTolmetin may increase the anticoagulant activities of Rivaroxaban.
TositumomabThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Tositumomab.
TreprostinilTreprostinil may increase the anticoagulant activities of Rivaroxaban.
UrokinaseUrokinase may increase the anticoagulant activities of Rivaroxaban.
VenlafaxineVenlafaxine may increase the anticoagulant activities of Rivaroxaban.
VerapamilThe serum concentration of Rivaroxaban can be increased when it is combined with Verapamil.
VilazodoneVilazodone may increase the anticoagulant activities of Rivaroxaban.
Vitamin EVitamin E may increase the anticoagulant activities of Rivaroxaban.
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Rivaroxaban.
VortioxetineVortioxetine may increase the anticoagulant activities of Rivaroxaban.
WarfarinWarfarin may increase the anticoagulant activities of Rivaroxaban.
Food Interactions
  • Food should be taken with the 15 mg and 20 mg tablet. Food increases the bioavailability of the 20 mg dose.
  • Foods with antiplatelet/anticoagulants properties such as horseradish, gingko, ginger, garlic, feverfew
  • St. John's Wort is a CYP3A4 inducer and will decrease levels of rivaroxaban

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serine-type endopeptidase activity
Specific Function:
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
Gene Name:
F10
Uniprot ID:
P00742
Molecular Weight:
54731.255 Da
References
  1. Melillo SN, Scanlon JV, Exter BP, Steinberg M, Jarvis CI: Rivaroxaban for thromboprophylaxis in patients undergoing major orthopedic surgery. Ann Pharmacother. 2010 Jun;44(6):1061-71. doi: 10.1345/aph.1M681. Epub 2010 Apr 27. [PubMed:20424181 ]
  2. Ufer M: Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85. doi: 10.1160/TH09-09-0659. Epub 2010 Feb 2. [PubMed:20135071 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Mismetti P, Laporte S: [Rivaroxaban: clinical pharmacology]. Ann Fr Anesth Reanim. 2008 Dec;27 Suppl 3:S16-21. doi: 10.1016/S0750-7658(08)75142-6. [PubMed:19185782 ]
  2. Ufer M: Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85. doi: 10.1160/TH09-09-0659. Epub 2010 Feb 2. [PubMed:20135071 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
This enzyme metabolizes arachidonic acid predominantly via a NADPH-dependent olefin epoxidation to all four regioisomeric cis-epoxyeicosatrienoic acids. One of the predominant enzymes responsible for the epoxidation of endogenous cardiac arachidonic acid pools.
Gene Name:
CYP2J2
Uniprot ID:
P51589
Molecular Weight:
57610.165 Da
References
  1. Ufer M: Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85. doi: 10.1160/TH09-09-0659. Epub 2010 Feb 2. [PubMed:20135071 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Cabral KP: Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis. 2013 Aug;36(2):133-40. doi: 10.1007/s11239-013-0929-5. [PubMed:23645472 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Walenga JM, Adiguzel C: Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract. 2010 Jun;64(7):956-67. doi: 10.1111/j.1742-1241.2009.02286.x. [PubMed:20584229 ]
  2. Chen T, Lam S: Rivaroxaban: an oral direct factor Xa inhibitor for the prevention of thromboembolism. Cardiol Rev. 2009 Jul-Aug;17(4):192-7. doi: 10.1097/CRD.0b013e3181aa2154. [PubMed:19525681 ]
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:18 / Updated on July 02, 2016 01:51